Novo Nordisk's 2030 Reckoning: Can a Pipeline of Deals Outrun Semaglutide's Patent Cliff?
Published on 09/26/2026 at 19:41 | Editorial boerse-global.de
Novo Nordisk is spending heavily to ensure its next act arrives before its current one exits. The Danish drugmaker has strung together a series of licensing deals and clinical wins in recent weeks, yet its shares closed Friday at EUR 34.05 — down 23% year-to-date and roughly 38% below their 52-week high. Investors, it seems, are not yet convinced the future is fully funded.
At the heart of the push is a worldwide licensing agreement signed with Sweden's Nanexa, worth up to around EUR 1.17 billion (roughly USD 1.33 billion). The pact centers on PharmaShell, an atomic layer deposition technology designed to stretch drug release so that peptide-based therapies for obesity, type 2 diabetes and cardiometabolic disease need only be injected monthly or quarterly. Nanexa stands to receive a EUR 615 million upfront payment, plus milestone payments of up to EUR 1.165 billion and low single-digit royalties.
The deal is not an isolated move. On September 17, Novo Nordisk struck a research and licensing partnership with Orbis Medicines worth up to USD 1.4 billion to develop oral therapies, alongside a strategic equity stake in the company whose size was not disclosed. A day earlier, it teamed up with Anthropic to deploy Claude models in drug discovery and software development. Taken together, the agreements sketch a company determined to diversify how its medicines reach patients — and to blunt the challenge from US rival Eli Lilly.
Oral Pills and the Race for Delivery Formats
Chief executive Mike Doustdar told Reuters on Tuesday that alternative delivery methods carry enormous potential. In his view, oral obesity pills could capture as much as half the global market for weight-loss medicines by 2030. Because competitors have concentrated largely on injectables, Doustdar argues that gives Novo Nordisk a long-term edge.
Whether that technological leap lands in time is the question weighing on shareholders. At a capital markets day days ago, BMO analyst Evan Seigerman noted that projected revenue growth of 3.6% is already priced in. In his assessment, management now has to prove it can execute.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Clinical Data Bolster the Case
The pipeline delivered fresh evidence on Monday. CagriSema, a combination of cagrilintide and semaglutide, produced a 12.4% weight reduction after 60 weeks in the Phase 3 REIMAGINE 5 trial, beating a 5-milligram dose of Eli Lilly's tirzepatide, which achieved 9.1%. In a separate late-stage obesity study, REDEFINE 9, the drug delivered 21% weight loss versus placebo after 68 weeks. Both trials also showed good tolerability.
On that clinical foundation, Novo Nordisk aims to bring more than five new blockbuster medicines to market by 2030. By 2035, management is targeting additional pipeline revenue exceeding DKK 150 billion. The company says its balance sheet is strong enough to fund larger acquisitions should the right opportunity arise.
The Semaglutide Concentration Problem
Those ambitions exist because the current revenue base is dangerously narrow. Semaglutide accounts for roughly 75% of total sales this year, according to analysts — a dependence that markets increasingly treat as a concentration risk. Patent protection for the molecule expires in Europe in 2031 and in the US in 2032. If approvals for successor treatments slip or fail, Novo Nordisk faces a stretch of flat or shrinking revenue.
The market is already pricing in that anxiety. On Tuesday, another analyst cut their price target to DKK 245 from DKK 265, according to media reports, as investors apply a stricter lens to the company's rich valuation against the mid-decade patent cliff.
Buybacks Offer Some Support
One counterweight is the ongoing capital return program. As of September 18, Novo Nordisk had repurchased about 34.2 million of its own B shares since early February, for a total transaction volume of roughly DKK 9.6 billion. Buybacks of that scale shore up earnings per share and signal the board's confidence in its own earnings power.
Execution Risk Cuts Both Ways
The strategy carries real hazards. Doustdar urged staff on September 15 to build a more customer-focused culture and regain ground lost to Eli Lilly, while management faces mounting questions about its pricing power. Expensive licensing deals add financial risk: payments like the potential EUR 1.17 billion for Nanexa flow into projects whose commercial payoff may take years to materialize. Setbacks in clinical phases or regulatory delays could quickly undermine the optimistic revenue targets.
For investors, the strategic question is whether the current weakness is an entry point or the start of a longer slump. As long as clinical development of candidates like CagriSema advances on schedule and the balance sheet retains room for strategic deals, a re-rating remains plausible. If confidence in the long-term pipeline forecasts cracks, or competition forces deeper price concessions, further declines loom.
The FDA Decision That Sets the Next Marker
The near-term direction hinges on a single milestone: the US Food and Drug Administration's approval decision on CagriSema in the fourth quarter of 2026. A positive verdict would be the first operational proof that Novo Nordisk can bring its next-generation blockbusters to market in time. A delay would only intensify fears about the approaching patent expiry. Until then, the company's deals and data must carry the stock — and the market is watching closely for signs that the pipeline can outpace the clock.
Ad
Novo Nordisk Stock: New Analysis - 26 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
